Sigma Minus Method
Sigma Minus Method - Related Videos
11:37
Sigma's Non-specific Protease Activity Assay - Casein as a Substrate
0 Views •
Cited by 414 •
2008
Proteases break peptide bonds. In the lab, it is often necessary to measure and/or compare the activity of proteases. Sigma's non-specific protease activity assay may be used as a standardized procedure to determine the activity of proteases.
12:39
Rapid Genotyping of Mouse Tissue Using Sigma's Extract-N-Amp Tissue PCR Kit
0 Views •
Cited by 4 •
2008
The complete genotyping of a mouse tail sample, including tissue digestion and PCR readout, is done in one and a half hours using Sigma's SYBR Green Extract-N-Amp Tissue PCR kit.
09:00
Use of the Protease Fluorescent Detection Kit to Determine Protease Activity
0 Views •
Cited by 15 •
2009
The Protease Fluorescent Detection Kit is designed for the measurement of protease activity using fluorometry. It is also suitable for detection of trace amounts of protease contamination. The method is based on the proteolytic hydroysis of a proprietary formulation of a FITC-labeled casein substrate.
09:11
Genome Editing with CompoZr Custom Zinc Finger Nucleases (ZFNs)
0 Views •
Cited by 28 •
2012
The CompoZr Custom Zinc-Finger Nuclease (ZFN) Service enables precise genome editing in any organism or cell line at any locus defined by the user. This article describes the process for the design, manufacture, validation and implementation of the CompoZr Custom ZFN Service.
11:36
Simple Method for Fluorescence DNA In Situ Hybridization to Squashed Chromosomes
0 Views •
Cited by 73 •
2015
Here, we present a simple method for performing fluorescence DNA in situ hybridization (DNA ISH) to visualize repetitive heterochromatic sequences on slide-mounted chromosomes. The method requires minimal reagents and it is versatile for use with short or long probes, different tissues, and detection with fluorescence or non-fluorescence-based signals.
FAQs
The logarithmic plot converts the remaining amount to be excreted into a form that can be evaluated over time. When the plotted values follow the expected pattern, the slope provides the elimination rate constant. That constant supports estimation of the drug’s half-life, allowing researchers to quantify elimination from urinary recovery data.
The total amount eventually recovered provides the reference for determining how much drug remains to be excreted at each time point. Subtracting cumulative recovery from this reference creates the values used in the analysis. Without this remainder, the method cannot construct the time-based profile needed to estimate elimination behavior.
First-order elimination can be characterized by examining whether the logarithm of the remaining excretable amount changes consistently with time. A suitable time relationship produces a slope that represents the elimination rate constant. This assessment helps distinguish a measurable elimination pattern in urinary data and supports subsequent half-life estimation and pharmacokinetic modeling.
Researchers first obtain urinary recovery measurements at successive time points and determine cumulative recovery for each interval. They then compare each cumulative value with the total amount eventually recovered to calculate the remaining amount. Finally, they plot that remainder logarithmically against time and interpret the resulting slope as the elimination rate constant.
The method is useful when investigators need to characterize drug elimination from urinary excretion data. It can support evaluation of renal excretion profiles, estimation of half-life, and development of pharmacokinetic models. These results may contribute to drug-dosing decisions and therapeutic monitoring by describing how a drug is eliminated over time.
Applying the same urinary recovery analysis across patients provides elimination-related measurements that can be compared between individuals. Differences in the calculated elimination rate or half-life may help describe variation in drug disposition. In clinical research, these comparisons can add context to therapeutic monitoring, dosing considerations, and interpretation of renal excretion profiles.